These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7643714)

  • 1. Effect of four potassium channel agonists on bupivacaine-induced toxicity in mice.
    Gantenbein M; Attolini L; Bruguerolle B
    Life Sci; 1995; 57(10):PL113-6. PubMed ID: 7643714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of putative activators of K+ channels in mouse pancreatic beta-cells.
    Garrino MG; Plant TD; Henquin JC
    Br J Pharmacol; 1989 Nov; 98(3):957-65. PubMed ID: 2531623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of putative activators of K+ channels on pancreatic B-cell function.
    Plant TD; Garrino MG; Henquin JC
    Pflugers Arch; 1989; 414 Suppl 1():S152-3. PubMed ID: 2528721
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil.
    Wilson C; Coldwell MC; Howlett DR; Cooper SM; Hamilton TC
    Eur J Pharmacol; 1988 Aug; 152(3):331-9. PubMed ID: 2851450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cromakalim, pinacidil and nicorandil on cardiac refractoriness and arterial pressure in open-chest dogs.
    Spinelli W; Follmer C; Parsons R; Colatsky T
    Eur J Pharmacol; 1990 Apr; 179(3):243-52. PubMed ID: 2142089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pinacidil, cromakalim, and nicorandil on potassium currents of rat basilar artery smooth muscle.
    Zhang H; Stockbridge N; Weir B
    Adv Exp Med Biol; 1991; 304():531-41. PubMed ID: 1839488
    [No Abstract]   [Full Text] [Related]  

  • 7. Potassium channel agonists modify the local anaesthetic activity of bupivacaine in mice.
    Gantenbein M; Attolini L; Bruguerolle B
    Can J Anaesth; 1996 Aug; 43(8):871-6. PubMed ID: 8840069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil.
    Yanagisawa T; Teshigawara T; Taira N
    Br J Pharmacol; 1990 Sep; 101(1):157-65. PubMed ID: 2149290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of calcium channel blockers on bupivacaine-induced toxicity.
    Bruguerolle B
    Life Sci; 1993; 53(21):PL349-53. PubMed ID: 8231633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD; Clapham JC; Wilson C; Hamilton TC
    J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle.
    Yanagisawa T; Hashimoto H; Taira N
    Br J Pharmacol; 1988 Oct; 95(2):393-8. PubMed ID: 2852521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K+ channel openers.
    McPherson GA; Stork AP
    Br J Pharmacol; 1992 Jan; 105(1):51-8. PubMed ID: 1534504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glibenclamide is a competitive antagonist of cromakalim, pinacidil and RP 49356 in guinea-pig pulmonary artery.
    Eltze M
    Eur J Pharmacol; 1989 Jun; 165(2-3):231-9. PubMed ID: 2528466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K+ channel activators, acute glucose tolerance and glibenclamide-induced hypoglycaemia in the hypertensive rat.
    Clapham JC; Trail BK; Hamilton TC
    Eur J Pharmacol; 1994 May; 257(1-2):79-85. PubMed ID: 8082711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Potassium channel activators: comparative structural study of pinacidil, diazoxide and cromakalim].
    Dupont L; Pirotte B; de Tullio P; Masereel B; Delarge J
    Ann Pharm Fr; 1995; 53(5):201-8. PubMed ID: 7503508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological properties of ATP-sensitive K+ channels in mammalian skeletal muscle cells.
    Allard B; Lazdunski M
    Eur J Pharmacol; 1993 Jun; 236(3):419-26. PubMed ID: 8359200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advance in pharmacology of potassium channels in cardiovascular system and their clinical use].
    Wu Y; Fang D
    Zhonghua Yi Xue Za Zhi; 1992 Mar; 72(3):180-3. PubMed ID: 1319810
    [No Abstract]   [Full Text] [Related]  

  • 18. [Potassium channel activators. Perspectives in the treatment of arterial hypertension].
    Giudicelli JF; Richer C; Berdeaux A
    Presse Med; 1991 Jan; 20(2):75-81. PubMed ID: 1825708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
    Satoh K
    Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flumazenil and bupivacaine-induced toxicity: inverse agonist type activity.
    Bruguerolle B; Emperaire N
    Life Sci; 1991; 49(23):PL185-8. PubMed ID: 1943471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.